StockNews.AI
SLP
StockNews.AI
75 days

Simulations Plus Releases ADMET Predictor® 13

1. Simulations Plus releases ADMET Predictor® 13, enhancing drug discovery capabilities. 2. The platform focuses on ML for molecule design and optimization.

2m saved
Insight
Article

FAQ

Why Bullish?

The launch of ADMET Predictor® 13 showcases SLP's innovation and potential market growth, similar to past successful releases that led to stock price increases.

How important is it?

The introduction of a new product in a competitive market like biopharma tends to positively influence investor sentiment and future earnings potential.

Why Short Term?

Immediate market reaction expected from the announcement, historically seen in similar product launches that boosted SLP's stock.

Related Companies

VRTXAMGNGILD
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13.

Related News